Clinical Trial Update: Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab with or without tremelimumab after palliative hypofractionated radiotherapy for hepatocellular carcinoma is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Imfinzi (durvalumab) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Mary Feng, MD | Conditions: Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Status: RECRUITING